Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 2:15 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 2:15 p.m. ET. Interested parties can access the presentation via the 'Investors' section on Nabriva's website. Nabriva is focused on developing innovative anti-infective treatments like XENLETA® for community-acquired bacterial pneumonia and CONTEPO™ for complicated urinary tract infections. The company has a partnership with Merck to market SIVEXTRO® in the U.S.
Details
News Market Reaction – NBRV
The recorded move for NBRV in the trading session of this news was +5.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 2:15p.m. ET.
The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin), the first pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTIs), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. For more information, please visit https://www.nabriva.com
CONTACTS:
For Investors
Kim Anderson
Nabriva Therapeutics plc
IR@Nabriva.com
For Media
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.